- Home
- NCNA vs LIXT Comparison
NCNA vs LIXT Comparison
Compare NCNA & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- LIXT
- Stock Information
- Founded
- NCNA 1997
- LIXT 2005
- Country
- NCNA United Kingdom
- LIXT United States
- Employees
- NCNA N/A
- LIXT N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- LIXT Health Care
- Exchange
- NCNA Nasdaq
- LIXT Nasdaq
- Market Cap
- NCNA 4.4M
- LIXT 4.2M
- IPO Year
- NCNA 2017
- LIXT N/A
- Fundamental
- Price
- NCNA $1.49
- LIXT $1.62
- Analyst Decision
- NCNA Buy
- LIXT
- Analyst Count
- NCNA 2
- LIXT 0
- Target Price
- NCNA $25.00
- LIXT N/A
- AVG Volume (30 Days)
- NCNA 138.4K
- LIXT 1.8M
- Earning Date
- NCNA 11-26-2024
- LIXT 11-12-2024
- Dividend Yield
- NCNA N/A
- LIXT N/A
- EPS Growth
- NCNA N/A
- LIXT N/A
- EPS
- NCNA N/A
- LIXT N/A
- Revenue
- NCNA N/A
- LIXT N/A
- Revenue This Year
- NCNA N/A
- LIXT N/A
- Revenue Next Year
- NCNA N/A
- LIXT N/A
- P/E Ratio
- NCNA N/A
- LIXT N/A
- Revenue Growth
- NCNA N/A
- LIXT N/A
- 52 Week Low
- NCNA $1.49
- LIXT $1.31
- 52 Week High
- NCNA $19.40
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- NCNA 34.09
- LIXT 43.04
- Support Level
- NCNA $1.53
- LIXT $1.56
- Resistance Level
- NCNA $1.66
- LIXT $1.87
- Average True Range (ATR)
- NCNA 0.09
- LIXT 0.23
- MACD
- NCNA 0.05
- LIXT -0.03
- Stochastic Oscillator
- NCNA -3.70
- LIXT 8.33
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.